These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38185192)

  • 21. Glucagon-like peptide 1 excites hypocretin/orexin neurons by direct and indirect mechanisms: implications for viscera-mediated arousal.
    Acuna-Goycolea C; van den Pol A
    J Neurosci; 2004 Sep; 24(37):8141-52. PubMed ID: 15371515
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exploratory trial of intranasal administration of glucagon-like peptide-1 in Japanese patients with type 2 diabetes.
    Ueno H; Mizuta M; Shiiya T; Tsuchimochi W; Noma K; Nakashima N; Fujihara M; Nakazato M
    Diabetes Care; 2014 Jul; 37(7):2024-7. PubMed ID: 24667460
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine.
    Hansen L; Deacon CF; Orskov C; Holst JJ
    Endocrinology; 1999 Nov; 140(11):5356-63. PubMed ID: 10537167
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Brain region specific glucagon-like peptide-1 receptors regulate alcohol-induced behaviors in rodents.
    Vallöf D; Kalafateli AL; Jerlhag E
    Psychoneuroendocrinology; 2019 May; 103():284-295. PubMed ID: 30771711
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glucagon-Like Peptide-1 Regulates the Proopiomelanocortin Neurons of the Arcuate Nucleus both Directly and Indirectly via Presynaptic Action.
    Péterfi Z; Szilvásy-Szabó A; Farkas E; Ruska Y; Pyke C; Knudsen LB; Fekete C
    Neuroendocrinology; 2021; 111(10):986-997. PubMed ID: 33152734
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of glial cell-line derived neurotropic factor family receptor alpha2 in the actions of the glucagon-like peptides on the murine intestine.
    McDonagh SC; Lee J; Izzo A; Brubaker PL
    Am J Physiol Gastrointest Liver Physiol; 2007 Aug; 293(2):G461-8. PubMed ID: 17585017
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Repositioning of dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 agonists as potential neuroprotective agents.
    Mousa SA; Ayoub BM
    Neural Regen Res; 2019 May; 14(5):745-748. PubMed ID: 30688255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glucagon-like peptide (GLP)-2 action in the murine central nervous system is enhanced by elimination of GLP-1 receptor signaling.
    Lovshin J; Estall J; Yusta B; Brown TJ; Drucker DJ
    J Biol Chem; 2001 Jun; 276(24):21489-99. PubMed ID: 11262390
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis.
    Drucker DJ
    Mol Endocrinol; 2003 Feb; 17(2):161-71. PubMed ID: 12554744
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the effects of intracerebroventricular administration of glucagon-like peptides 1 and 2 on hypothalamic appetite regulating factors and sleep-like behavior in chicks.
    Kewan A; Shimatani T; Saneyasu T; Kamisoyama H; Honda K
    Neurosci Lett; 2022 Jan; 768():136362. PubMed ID: 34838926
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glucagon-like peptide-1 protects hippocampal neurons against advanced glycation end product-induced tau hyperphosphorylation.
    Chen S; An FM; Yin L; Liu AR; Yin DK; Yao WB; Gao XD
    Neuroscience; 2014 Jan; 256():137-46. PubMed ID: 24183963
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier.
    Kastin AJ; Akerstrom V; Pan W
    J Mol Neurosci; 2002; 18(1-2):7-14. PubMed ID: 11931352
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Role of Glucagon-Like Peptide 1 (GLP1) in Type 3 Diabetes: GLP-1 Controls Insulin Resistance, Neuroinflammation and Neurogenesis in the Brain.
    Bae CS; Song J
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165354
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glucagon like peptide-1 accelerates colonic transit via central CRF and peripheral vagal pathways in conscious rats.
    Nakade Y; Tsukamoto K; Iwa M; Pappas TN; Takahashi T
    Auton Neurosci; 2007 Jan; 131(1-2):50-6. PubMed ID: 16938493
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intracoronary glucagon-like peptide 1 preferentially augments glucose uptake in ischemic myocardium independent of changes in coronary flow.
    Moberly SP; Berwick ZC; Kohr M; Svendsen M; Mather KJ; Tune JD
    Exp Biol Med (Maywood); 2012 Mar; 237(3):334-42. PubMed ID: 22345302
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glucagon-like peptide 2 function in domestic animals.
    Burrin DG; Stoll B; Guan X
    Domest Anim Endocrinol; 2003 Mar; 24(2):103-22. PubMed ID: 12586312
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhanced brain distribution and pharmacodynamics of rivastigmine by liposomes following intranasal administration.
    Yang ZZ; Zhang YQ; Wang ZZ; Wu K; Lou JN; Qi XR
    Int J Pharm; 2013 Aug; 452(1-2):344-54. PubMed ID: 23680731
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
    Secher A; Jelsing J; Baquero AF; Hecksher-Sørensen J; Cowley MA; Dalbøge LS; Hansen G; Grove KL; Pyke C; Raun K; Schäffer L; Tang-Christensen M; Verma S; Witgen BM; Vrang N; Bjerre Knudsen L
    J Clin Invest; 2014 Oct; 124(10):4473-88. PubMed ID: 25202980
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evidence of metabolic memory-induced neurodegeneration and the therapeutic effects of glucagon-like peptide-1 receptor agonists via Forkhead box class O.
    Chen S; Tang Q; Wang Y; Xu Z; Chen ST; Sun Y; Yao WB; Gao XD
    Biochim Biophys Acta Mol Basis Dis; 2019 Feb; 1865(2):371-377. PubMed ID: 30465895
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficiency of cell-penetrating peptides on the nasal and intestinal absorption of therapeutic peptides and proteins.
    Khafagy el-S; Morishita M; Kamei N; Eda Y; Ikeno Y; Takayama K
    Int J Pharm; 2009 Oct; 381(1):49-55. PubMed ID: 19646515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.